# A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy

> **NCT02813785** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 565 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02813785
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-01
- **Primary completion:** 2019-08-01
- **Final completion:** 2022-12-27
- **Target enrollment:** 565 (ACTUAL)
- **Last updated:** 2023-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02813785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02813785, "A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02813785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*